Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in ProCellEx® plant cell-based protein expression system, will release its Q2 2025 financial results on August 14, 2025.

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in ProCellEx® plant cell-based protein expression system, will release its Q2 2025 financial results on August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide corporate and regulatory updates.

The conference call will be accessible via multiple channels, including toll-free numbers for US and Israeli participants, and will feature a convenient Call me™ feature. A webcast replay will be available for two weeks following the presentation on the company's investor relations website.

Argus Aug 7 session

+2.03% close to close Open Argus

Details

News Market Reaction – PLX

On Aug 7, the day this news came out, PLX closed 2.03% above the previous close.

Data tracked by StockTitan Argus for the Aug 7 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call and webcast at 8:30 a.m. EDT

CARMIEL, Israel, Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2025 and provide a business and clinical update on August 14, 2025.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:
Date:	Thursday, August 14, 2025
Time:	8:30 a.m. Eastern Daylight Time (EDT)
Toll Free:	1-877-423-9813
International:	1-201-689-8573
Israeli Toll Free:	1-809-406-247
Conference ID:	13755073
Call me™:	https://tinyurl.com/6uc7hkxf
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
The conference will be webcast live from the Protalix website and will be available via the following links:
Company Link:	https://ir.protalix.com/news-events/events
Webcast Link:	https://tinyurl.com/yc272tbr
Conference ID:	13755073

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.

Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306 
mmoyer@lifesciadvisors.com

Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2025-financial-and-business-results-on-august-14-2025-302524577.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Protalix BioTherapeutics (PLX) release Q2 2025 earnings?

Protalix BioTherapeutics will release its Q2 2025 financial results on August 14, 2025 at 8:30 a.m. EDT.

How can investors access Protalix BioTherapeutics' Q2 2025 earnings call?

Investors can access the call through multiple channels: US toll-free (1-877-423-9813), international dial-in, webcast on the company's website, or using the Call me™ feature. Conference ID is 13755073.

Will there be a replay available of Protalix BioTherapeutics' Q2 2025 earnings call?

Yes, a replay of the call will be available for two weeks on the Events Calendar of the Investors section of the company's website.

What does Protalix BioTherapeutics' ProCellEx technology do?

ProCellEx® is Protalix's proprietary plant cell-based protein expression system used for the development and production of recombinant therapeutic proteins.